J
J. Alejandro Pérez-Fidalgo
Researcher at University of Valencia
Publications - 11
Citations - 1114
J. Alejandro Pérez-Fidalgo is an academic researcher from University of Valencia. The author has contributed to research in topics: KRAS & Breast cancer. The author has an hindex of 8, co-authored 11 publications receiving 864 citations.
Papers
More filters
Journal ArticleDOI
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
TL;DR: The present review summarizes the advances that have allowed researchers to both better classify and study breast cancer, as well as explore some of the most important signaling pathways.
Journal ArticleDOI
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyungmin Lee,Jennifer M. Giltnane,Justin M. Balko,Luis J. Schwarz,Angel Guerrero-Zotano,Katherine E. Hutchinson,Mellissa J. Nixon,Monica V. Estrada,Violeta Sanchez,Melinda E. Sanders,Taekyu Lee,Henry L. Gomez,Ana Lluch,J. Alejandro Pérez-Fidalgo,Melissa M. Wolf,Gabriela Andrejeva,Jeffrey C. Rathmell,Stephen W. Fesik,Carlos L. Arteaga +18 more
TL;DR: The data suggest that MYC and MCL1 confer resistance to chemotherapy by expanding CSCs via mtOXPHOS and targeting mitochondrial respiration and HIF-1α may reverse chemotherapy resistance in TNBC.
Journal ArticleDOI
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
Udai Banerji,Emma Dean,J. Alejandro Pérez-Fidalgo,Gerald Batist,Philippe L. Bedard,Benoit You,Shannon N. Westin,Peter Kabos,Michelle D. Garrett,Mathew Tall,Helen Ambrose,J. Carl Barrett,T. Hedley Carr,S.Y. Amy Cheung,Claire Corcoran,Marie Cullberg,Barry R. Davies,Elza C. de Bruin,Paul Elvin,Andrew Foxley,Peter Lawrence,Justin P.O. Lindemann,Rhiannon Maudsley,Martin Pass,Vicky Rowlands,Paul Rugman,Gaia Schiavon,James W.T. Yates,Jan H.M. Schellens,Jan H.M. Schellens +29 more
TL;DR: At the recommended phase II dose, AZD5363 was well tolerated and achieved plasma levels and robust target modulation in tumors, and proof-of-concept responses were observed in patients with PIK3CA-mutant cancers treated with AZD 5363.
Journal ArticleDOI
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel Guerrero-Zotano,Thomas Stricker,Luigi Formisano,Katherine E. Hutchinson,Daniel G. Stover,Kyungmin Lee,Luis J. Schwarz,Jennifer M. Giltnane,Monica V. Estrada,Valerie M. Jansen,Alberto Servetto,Joaquín Gavilá,J. Alejandro Pérez-Fidalgo,Ana Lluch,Antonio Llombart-Cussac,Mohamed Amine Bayar,Mohamed Amine Bayar,Stefan Michiels,Stefan Michiels,Fabrice Andre,Monica Arnedos,V. Guillem,Amparo Ruiz-Simon,Carlos L. Arteaga +23 more
TL;DR: In tumors resistant to prolonged neoadjuvant letrozole, a gene expression signature of E2F4 target activation is identified, suggesting a potential benefit of adjuvant CDK4/6 inhibitors in patients with ER+ breast cancer who fail to respond to preoperative estrogen deprivation.
Proceedings ArticleDOI
Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.
Jeffrey R. Infante,Josep Tabernero,Andrés Cervantes,Shadia I. Jalal,Howard A. Burris,Teresa Macarulla,J. Alejandro Pérez-Fidalgo,Rachel Neuwirth,Chirag Patel,Esha Gangolli,Rachael L. Brake,Jeffrey Sturm,Eric H. Westin,Michael S. Gordon +13 more
TL;DR: This first-in-human study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of oral MLN0128.